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Abstract: The characterization of human microglia has been hampered by poor availability of human
cell sources. However, microglia is involved in the physiopathology of multiple sclerosis, Alzheimer’s
disease, Parkinson’s disease, HIV dementia, retinal degenerative diseases, cancer, and many other
conditions. Therefore, there is an important need to have experimental paradigms of human microglia
characterized and usable to study the role of microglia in the different pathologies in which it is
involved. In the present work, we carried out an extensive characterization of Immortalized Human
Microglia—SV40 cell line (IMhu), marketed by Applied Biological Material. The functional response
of IMhu to a large variety of stimuli was studied. In particular, we investigated morphology, mortality,
and changes in the production of different cytokines and chemokines, both under basal conditions and
after stimulation. Moreover, western blotting analysis was conducted on phospho-mTOR (Ser 2448)
and downstream parameters, p-P70S6K and 4EBP1, in order to understand if IMhu can be used for
evaluations of mTOR pathway. In conclusion, IMhu cells proved to be a useful experimental model
to investigate the physiopathology of inflammatory disease that involved microglia cells, including
pathological conditions that involved the mTOR pathway.
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1. Introduction
Microglia, myeloid cells resident in the brain parenchyma, represent the first line of immune defense
within the central nervous system (CNS), playing a role in synaptic architecture and neurogenesis [1,2].
These cells are often described as either resting (i.e., ramified) or activated, but these terms fail
to convey the dynamic remodeling of their fine processes and constitutive immune-surveillance
activity. Chronic activation of microglia is believed to exert detrimental effects, which underlie the
pathogenic mechanisms common to many neurodegenerative diseases. Microglia is involved in the
physiopathology of multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, HIV dementia, retinal
degenerative diseases, cancer, and many other conditions [3–5].
At present, different phenotypes of microglia are described, each having specific functions.
In particular, microglia is classified into four main states or phenotypes. Under certain pathological
conditions, microglial cells are polarized into the M1 type, releasing pro-inflammatory factors and
causing neuro-inflammatory responses. When inflammation fades away, or in the presence of a tumor
microenvironment, microglia shift into the alternatively activated M2 phenotype, which in turn can
be distinguished into the M2a, M2b, or M2c subtypes. Overall, the M2 phenotype is associated to
neuroprotection and tumor growth [6,7].
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Microglial activation and function were extensively investigated in animal experimental models
(both rats and mice). In contrast, the characterization of human microglia has been hampered by
poor availability of human cell sources. To overcome this problem, in the last few years human
immortalized microglial cell lines have been developed, and different human microglia cell lines have
been commercialized.
The Immortalized Human Microglia—SV40 cell line (IMhu) is marketed by Applied Biological
Material (ABM). IMhu are derived from Primary Human Microglia Cells (>99% purity), and maintained
the microglial marker CD68 and NGF, as shown by RT-PCR (https://www.abmgood.com/Immortalized-
Microglia-SV40-T0251.html#documents). These cells are suitable for studying the role of human
microglia in health and disease. Thus far, iMhu have been described as an experimental paradigm in a
number of reports [5,8–15].
In the present work, an extensive characterization of iMhu has been carried out; the response of
these cells to pro-inflammatory and anti-inflammatory stimuli has been evaluated. Many conditions of
M1 and M2 activation have been tested. Moreover, 2-h experiments in the presence of M1 stimuli were
specifically addressed to see whether iMhu cells could be used for evaluation of the pro-inflammatory
activated mTOR pathway.
2. Methods
2.1. Materials
Cell culture reagents (Dulbecco’s modified Eagle’s medium (DMEM—Cat. No.: 10-013-CVR),
DMEM-F12 (Cat. No.: D6421 and fetal calf serum (FCS—Cat. No.: 10091-148)) were from
Invitrogen Corporation (Paisley, Scotland) while Prigrow III (Cat. No.: TM003) was from Applied
Biological Materials Inc. (Richmond, QC, Canada). Antibiotics were from Biochrom AG (Cat. No.:
A2212—Berlin, Germany). The human recombinant interleukin 1β (IL1β—Cat. No 201-LB), human
IFN γ, and recombinant human tumor necrosis factorα (TNFα—Cat. No MAB210-SP) were purchased
from R & D System (Minneapolis, MN, USA). The human recombinant interleukin 4 (IL4—Cat. No.:
ENZ-PRT180-0020) and human recombinant interleukin 13 (IL13—Cat. No.: ENZ-PRT183-0010)
were purchased from Enzo Life Sciences, Inc. (Farmingdale, NY, USA). β-actin (clone AC-74—Cat.
No.: A5316) mouse monoclonal antibody was from Sigma-Aldrich (St.Louis, MO, USA), rabbit
polyclonal anti-phospho (ser-2448) mTOR (Cat. No.: NB600-607) was purchased from Novus Biological
(Littleton, CO, USA), mouse monoclonal p-p70 S6K (Cat. No.: SC-8416) was purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), rabbit polyclonal 4EBP1 (Cat. No.: A300-501A)
was purchased from Bethyl Laboratories, Inc (Montgomery, TX, USA), anti-rabbit was purchased
from Jackson ImmunoResearch Laboratories, Inc. (Cat. No.: 111-035-045, West Grove, PA, USA),
and anti-mouse was purchased from Sigma-Aldrich (Cat. No.: A3682—St.Louis, MO, USA).
2.2. Cell Cultures
Immortalized Human Microglia—SV40 (IMhu; Cat.No.: T0251) was purchased from Applied
Biological Materials Inc (Richmond, QC, Canada). IMhu was grown in Prigrow III media containing
10% FCS and antibiotics in Applied Biological Materials Inc. (Richmond, QC, Canada) PriCoat™ T25
flasks (Cat. No.: G299) and seeded at 40,000 cell per cm2 density; experimental conditions were reached
with DMEM-F12 at a low concentration of FCS (1%) in handmade Corning T25 coated flask with
collagen I at 0.1mg/mL (Cat. No.: A10483-01—Gibco Life Technologies Corporation, Grand Island,
NY, USA) concentration. Briefly, flasks were treated with collagen 0.1mg/mL in PBS with calcium
and magnesium (Cat. No.: D1283—Sigma-Aldrich, St.Louis, MO, USA) for 1 h at 37 ◦C; after that,
two washes in PBS with calcium and magnesium were needed and flasks were used to seed the cells.
Cells were splitted at the 80% of the confluence. All the experiments received institutional approval.
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2.3. M1 and M2 Stimulation
A mix of pro-inflammatory cytokines, namely 10 ng/mL TNFα, 50 ng/mL IL1β, and 20 ng/mL
IFNΥ, referred to as TII group was used to reach a M1 stimulation. In particular, 24 h after the seeding
IMhu cells were treated with TII and after another 24 h, the experiments were stopped.
Similarly, to reach M2 stimulation with IL13 in the range of concentrations 50–100–200 ng/mL,
or with IL4 in the range of concentrations 10–20–40 ng/mL, the IMhu cells were activated 24 h after the
seeding and the experiments were conducted for another 24 h.
All the experiments were carried out in Pigrow III, DMEM/F12 or in DMEM with 1% FBS.
2.4. Viability and Mortality
The cell viability was detected using RealTime-Glo™ MT Cell Viability Assay (Cat. No.:
G9713—Promega, Madison, WI, USA) and the number of nonviable cells was detected using CellTox™
Green Cytotoxicity Assay (Cat. No.: G8742—Promega, Madison, WI, USA). The assays were conducted
following the manufacturer’s instructions.
2.5. LDH Assay
At the end of selected experiments, cell viability was assessed by measurement of the activity of
lactate dehydrogenase (LDH) released in the incubation media, using the CytoTox-96 kit from Promega
(Cat. No.: G1780, Madison, WI, USA), according to the manufacturer’s instructions.
2.6. Urea Assay
Urea levels in IMhu cells were detected by the QuantiChrom Urea Assay kit (Cat. No.:
DIUR-100—BioAssay System, Hayward, CA, USA), used according to the manufacturer’s instructions.
Briefly after 24 h of incubation with the tested substances, an aliquot of cell culture media (50 µL)
was mixed with 200 µL Urea Reagent (BioAssay system, Hayward, CA, USA) and the absorbance
measured at 430 nm in a spectrophotometric microplate reader (PerkinElmer Inc., Waltham, MA,
USA). A standard curve was generated during each assay in the range of concentrations 0–100 µg/mL
using urea as standard. In this range, standard detection resulted linear, and the minimum detectable
concentration of urea was 3.12µg/mL. The protein content in each sample was determined by Bradford’s
method (Cat. No.: 5000006—Bio-Rad, Hercules, CA, USA) using bovine serum albumin (BSA—Cat.
No.: A2153—Sigma-Aldrich, St.Louis, MO, USA) as standard.
Multiple Cytokines Analysis
Levels of cytokines, chemokines, and growth factors from cell lysates were detected using the
Proteome Profiler Human Cytokines XL kit (Cat. No.: ARY022B—R & D System, Minneapolis, MN,
USA). The assay was conducted following the manufacturer’s instructions.
2.7. Western Immunoblot
The cells were lysed in RIPA buffer [1 mM EDTA (Cat. No.: E7889), 150 mM NaCl (Cat. No.: S9888,
1% igepal (Cat. No.: I3021), 0.5% sodium deoxycholate (Cat. No.: D-6750), 50 mM Tris–HCl, pH 8.0 (Cat.
No.: T-3038) (Sigma-Aldrich, St.Louis, MO, USA), and 0.1% sodium dodecyl sulfate, SDS, (Cat. No.:
1610416—Bio-Rad, Hercules, CA, USA)] containing protease inhibitor cocktail diluted 1:250 (Cat. No.:
P8340—Sigma–Aldrich, St.Louis, MO, USA). The protein content in each sample was determined by
Bradford’s method (Bio-Rad, Hercules, CA, USA) using bovine serum albumin as standard. A 100 µg
aliquot of protein was mixed with 4× Bolt™ LDS Sample Buffer (Cat. No.: B0007—Novex, Carlsbad,
CA, USA) and 10× Bolt™ Sample Reducing Agent (Cat. No.: B0009—Novex, Carlsbad, CA, USA),
boiled for 5 min, and separated through 7% polyacrylamide SDS gels. Apparent molecular weights
were estimated by comparison to colored molecular weight markers (Cat. No.: LC5925—Invitrogen,
Carlsbad, CA, USA). After electrophoresis, proteins were transferred to nitrocellulose membranes
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by iBlot™ 2 Gel Transfer Device (Invitrogen, Carlsbad, CA, USA). The membranes were blocked
with 10% (w/v) low-fat milk (Cat. No.: 170-6404—Bio-Rad) in TBST (TBS Cat. No.: 28358—Thermo
Scientific™ (Rockford, IL, USA); Tween 20 Cat. No.: P5927—Sigma-Aldrich, St.Louis, MO, USA)
for 1 h at room temperature and incubated in the presence of the primary antibody overnight with
gentle shaking at 4 ◦C for phosphorylated m-TOR and p-P70S6K while membranes were incubated in
the iBind Flex Western Device (Cat. No.: SLF2000—Invitrogen, Carlsbad, CA, USA) for 4EBP1 and
β-actin. Primary antibodies for phosphorylated-mTOR, 4EBP1, p-P70S6K, and β-actin were used at
the final concentration of 1:1000. After the overnight incubation, primary antibody of p-m-TOR and
p-P70S6K was removed, membranes washed 3 times in TBST, and further incubated for 1 h at room
temperature in the presence of specific secondary antibody diluted 1:8000 for anti-mouse and 1:10,000
for anti-rabbit. Following three washes in TBST, bands were visualized incubating the membranes
in ECL reagents (Cat. No.: 34580; Cat. No.: 32106—Thermo Scientific™, Rockford, IL, USA) and
exposed to CL-XPosure™ Film (Cat. No.: 34090—Thermo Scientific™, Rockford, IL, USA). The same
membranes were washed 3 times in TBST and used for 4EBP1 and β-actin immunoblot in the iBind™
Flex Western Device with primary antibody used at a final concentration of 1:1000 and secondary
antibody diluted 1:3000 for anti-mouse and 1:15,000 for anti-rabbit.
2.8. Immunostaining
Cover glasses of 13 mm of diameter were coated with Collagen I 0.1 mg/mL or Poli-L-lysine
50 µg/mL (Cat. No.: A-003-E—Merck Millipore, Burlington, MA, USA) for 1 h at 37 ◦C, after that
three washes in PBS with calcium and magnesium were needed and used to seed the IMhu at
50,000–100,000 cells per well concentration. After 24 h from the treatment, cells were blocked with
PAF at 4% concentration in PBS with calcium and magnesium for 20 min at room temperature. After
three washes in PBS with calcium and magnesium, cells were blocked with BSA and incubated in
the presence of primary antibody. The incubation time was of 2 h for Phalloidin 1:400 (Cat. No.:
P1951—SigmaAldrich, St.Louis, MO, USA) and overnight for CD11b (Cat. No: NB110-89474—Novus
Biological, Littleton, CO, USA) 1:200; after three washes in PBS with calcium and magnesium in gentle
shaking, cells were incubated with secondary antibody for 1 h and mounted with Vectashield with
DAPI (Cat. No: H-1200—Vector Laboratories, Burlingame, CA, USA).
Statistical Analyses
Statistical analysis of the differences between pairs of groups was performed by Student’s t-test.
For multiple comparisons, ANOVA analysis, followed by Bonferroni’s post-test, was used. Statistical
significance was determined at α = 0.05 level. Differences were considered statistically significant
when p < 0.05. All the experiments were repeated at least three times.
3. Results
In the present work, Immortalized Human Microglia—SV40 (IMhu) cell line—has been
characterized under basal conditions and after cytokine stimulation.
After thawing, IMhu cells present with a triangular shape, typical of microglia cells in a resting
state. Figure 1 shows the morphology of cells 1, 2, 3, and 6 days after thawing. Figure shows that the
cells reach confluence (by about 80%–90%) 3 days after thawing; therefore, the cells need to be passed
3 days after thawing. Otherwise, some clusters of cells are detached (see day 6 in Figure 1). Thus,
our protocol established IMhu to be passed 3 days after thawing, and about twice weekly after the first
passage. In our experience, cells can be used for experiments up to 10 passages.
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Figure 1. Morphology of IMhu. (A–D) Morphology of IMhu cells, observed by phase-contrast
microscopy on days 1, 2, 3, and 6 after thawing. Magnitude 20×.
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IMhu are marketed as human microglia cells; in order to validate this datum, we carried out an
immunofluorescence staining for a marker specific of human microglia-macrophage lineage, namely
CD11b. One hundred percent cells were found positive for CD11b (Figure 2).
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activate IMhu toward a M1 phenotype. Figure 3 shows that cells, regardless of density at baseline, 
reach the highest number at 24 h of treatments (that means 48 hours after seeding). This finding 
suggests setting up experiments with 24-h treatments. As far as lethality is concerned, the number of 
dead cells increases significantly after 24 h of treatment, especially in the group seeded at a density 
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Figure 2. CD11b staini g in I . Cells w re stained with antibodies against the CD11b surface
antigen. (A) Panel A shows positive staining for CD11b and (B) panel B shows nuclear DAPI staining.
Magnitude 40×.
In order to characterize cell growth and lethality, real time course experiments (0–48 h) were
carried out seeding 5000, 10,000 or 20,000 cells per well, and measuring vitality and cellular mortality
in real-time (Figure 3). In these experiments, two different groups of microglial cells were investigated:
a control group treated with 1% serum medium, and a g oup stimulated with a ix of pro-inflammatory
cytokines, TNFα, IL1β, and IFNΥ, referred to as TII group. TII stimulus is used to activate IMhu toward
a M1 phenotype. Figure 3 shows that cells, regardless of density at baseline, reach the highest number
at 24 h of treatments (that means 48 h after seeding). This finding suggests setting up experiments with
24-h treatments. As far as lethality is concerned, the number of dead cells increases significantly after
24 h of treatment, especially in the group seeded at a density of 20,000 cells/well. In no case, TII proved
to affect cell viability (Figure 3).Brain Sci. 2019, 9, x FOR PEER REVIEW 7 of 12 
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determination of selected human cytokines and chemokines. After 24 h of stimulation with TII, cell 
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Figure 4 shows that TII exposure modifies IMhu cell morphology. In the control group, phalloidin
staining shows that the cells maintain a triangular shape with few branches, and are grouped in islets
whereas, in the group treated with TII, no grouping in islet is observed, but single cells form a network
with a large number of ramifications, which is the morphological presentation of activated microglia
Brain Sci. 2019, 9, x FOR PEER REVIEW 7 of 12 
 
Figure 3. Evaluation of cell viability and cell mortality of IMhu Cells. Panel (A) shows the growth of 
IMhu cell line under basal conditions in plain growth media and in the presence of TII with different 
number of seeded cells. Panel (B) shows cell mortality, respectively, in the presence of the indicated 
treatment. The fluorescence data indicates the non-viable cells, whereas the luminescence data 
indicates the viable cells. Two-way ANOVA analysis was carried out. 
Figure 4 shows that TII exposure modifies IMhu cell morphology. In the control group, 
phalloidin staining shows that the cells maintain a triangular shape with few branches, and are 
grouped in islets whereas, in t e group treated with TII, no grouping in islet is observed, but single 
cells form a netw rk with a large number of ramifications, whi h is the morphol gical presentat on 
of activated microglia  
 
(A) (B) 
Figure 4. F-actin immunostaining of IMhu. Morphological modifications of IMhu cells, observed 24 h 
post treatments, with a staining of F-actin with phalloidin-TRIC and fluorescence microscopy. (A) 
Cells under basal conditions or (B) after TII stimulation for 24 h. Magnitude 20×. 
To characterize the activation profile of TII-stimulated IMhu cells, we used the Cytokine XL kit 
from R & D (Minneapolis, MN, USA), a membrane-based antibody array for the parallel 
determination of selected human cytokines and chemokines. After 24 h of stimulation with TII, cell 
lysates were examined: 17 factors out of a total of 100 cytokines and chemokines were modified. In 
particular, 6 out of 17 factors were up-regulated, namely IFN-ϒ, IL32, IFN-ϒ-inducible protein 10 (IP-
10), Lipocalin-2, the chemokine IL8, and the adhesion molecule vascular cell adhesion molecule 1 
Figure 4. F-actin immunostaini g of IMhu. ical mod fications of IMhu cells, observed 24 h
post treatm nts, with a staining of F-actin with p alloidin-TRIC and fluorescence microscopy. (A) Cells
under basal conditions or (B) after TII stimulation for 24 h. Magnitude 20×.
To characterize the activation profile of TII-stimulated IMhu cells, we used the Cytokine XL kit
from R & D (Minneapolis, MN, USA), a membrane-based antibody array for the parallel determination
of selected human cytokines and chemokines. After 24 h of stimulation with TII, cell lysates were
examined: 17 factors out of a total of 100 cytokines and chemokines were modified. In particular, 6 out
of 17 factors were up-regulated, namely IFN-Υ, IL32, IFN-Υ-inducible protein 10 (IP-10), Lipocalin-2,
the chemokine IL8, and the adhesion molecule vascular cell adhesion molecule 1 (Vcam-1). Conversely,
11 out of 17 factors were down-regulated, in particular, angiopoietin-2, brain-derived neurotrophic
factor (BDNF), basic fibroblast growth factor (FGF basic), FGF-19, IL1α, IL5, Kallikrein 3, migration
inhibitory factor (MIF), MMP-9, thymus- and activation-regulated chemokine TARC/CCL17 and
transferrin receptor protein 1 TFR/CD71 (Figure 5 and Table 1).
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Table 1. Panel of cytokines, chemokines, growth factors, and other soluble proteins modified by
TII stimulation.
A † B ‡ hTII $
A11–12 Angiopoietin-2 −
A15–16 BDNF −
C9–10 FGF basic −
C13–14 FGF-19 −
D7–8 IFN-y +
D15–16 IL-1α −
E3–4 IL-5 −
E7–8 IL-8 +
F13–14 IL-32α/β/γ +
F19–20 IP-10 +
F23–24 Kallikrein 3 −
G5–6 Lipocalin-2 +
G13–14 MIF −
G23–24 MMP-9 −
I7–8 TARC/CCL17 −
I11–12 TfR/CD71 −
J11–12 VCAM-1 +
†, indicates the position on membrane of Figure 7; ‡, indicates the name of modified factors; $, indicates the results
under IL4 stimulation: “−“ indicates that the factor is down-regulated.
Apart from M1 activation, a series of experiments was carried out with IL4 or IL13 in order to
evaluate M2 activation. The release of urea was taken as a M2 marker in preliminary 24-h experiments
(Figure 6). Both IL4 and IL13 were able to significantly increase urea levels; statistically significant
increases were obtained with IL13 in the range of concentrations 50–100–200 ng/mL, and with IL4
in the range of concentrations 10–20–40 ng/mL (Figure 6). At the end of experiments, cell viability
was assessed by measurement of the activity of LDH released in the incubation media. None of
the treatments performed significantly increased LDH activity above control levels; in particular,
control has been taken as 100% and the data were expressed as % of control: 40 ng/mL IL4 measured
67% ± 3.9% and 200 ng/mL IL13 93% ± 8.2%. Responses to IL13 stimulation were dependent on the
medium used, since significant increases in urea levels were observed when IL13 was dissolved in
DMEM 1% serum; whereas, no increase was found if the medium was DMEM/F12 (data not shown).
Because of such variability, in all subsequent experiments IL4 20 ng/mL was preferred as a tool for M2
phenotype induction. Using IL4 as a stimulus, 4 out of 100 factors assessed with the above-mentioned
cytokine XL kit were modified. In particular, BDNF, FGF basic, FGF-19, and TARC/CC17 factors were
down regulated (Figure 7 and Table 2).
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Figure 7. Qualitative analysis of multiple cytokines, chemokines, growth factors, and other soluble
proteins in cellular lysates of IMhu after IL4 stimulation. Panel (A) shows the results from control group
and panel (B) shows the results from IL4 group. Yellow arrows indicate the down-regulated factors.
Finally, in order to ascertain whether IMhu microglia cell line is a useful model to investigate
mTOR pathway, 2-h experiments were conducted in the presence of TII analyzing ser2448—taken as
parameter of mTOR activation. We found that phosphorylated-mTOR is significantly upregulated by
TII administration, along with target proteins downstream of mTOR, p70S6K, and 4EBP1 (Figure 8).
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Table 2. Panel of cytokines, chemokines, growth factors, and other soluble proteins modified by
IL4 stimulation.
A † B ‡ hIL4 $
A15–16 BDNF −
C9–10 FGF basic −
C13–14 FGF-19 −
I7–8 TARC/CCL17 −
†, indicates the position on membrane of Figure 7; ‡, indicates the name of modified factors; $, indicates the results
under IL4 stimulation: “−“ indicates that the factor is down-regulated.
4. Discussion
In this work, we carried out an extensive characterization of IMhu immortalized microglia
cell line, involving the functional response of IMhu to a large variety of stimuli. In particular,
we investigated morphology, mortality, and changes in the production of different cytokines and
chemokines, both under basal conditions and after stimulation. Moreover, western blotting analysis
was conducted on phospho-mTOR (Ser 2448) and downstream parameters, p-P70S6K and 4EBP1,
in order to understand if IMhu can be used for evaluations of mTOR pathway.
Firstly, an evaluation of microglia-macrophage cell marker was conducted in order to confirm that
IMhu are indeed belonging to the microglia cell lineage (Figure 2). A number of markers are normally
used to address this issue, namely CD68, CD11b, or Iba-1 [16]. Among these markers, we focused on
CD11b, a member of the integrin family that couples with CD18 to form CR3 heterodimers. CD11b is
expressed on the surface of many leukocytes including monocytes, neutrophils, natural killer cells,
granulocytes, and macrophages/microglia. CD11b regulates leukocyte adhesion and migration. Apart
from its role in adhesion, CD11b acts as a receptor for complement C3bi, mediating complement-coated
particle uptake. Studies on CD11b antibodies lead to identify CD11b as a receptor for fibrinogen gamma
chain, factor X, and ICAM1, with a possible involvement in cell-mediated cytotoxicity, chemotaxis,
and phagocytosis [17]. A modified expression of Cd11b is observed in different states of microglia cell
activation; these changes were out of scope of investigation in this work.
In the study, we showed that exposure to TII is not associated to toxicity (Figure 3); these findings
confirm previous observations reported by Reiner et al. [15], obtained using TII in the same range of
doses. We gained initial evidence that TII challenge is able to induce changes in IMHu phenotype with
morphology experiments (Figure 4). These findings are in agreement with previous observations by
ourselves and other groups, obtained with different microglia sources and stimuli [18–20]. In all cases,
microglia are displayed as single cells forming a network, rather than a cluster of cells, and a large
number of ramifications.
In parallel with morphological changes, a pro-inflammatory activation leading to M1 phenotype
is also demonstrated by the up-regulation of 6 out of 17 modified inflammatory mediators, in particular
IFN-Υ, IL32, IP-10, lipocalin-2, and the chemokine IL8 and Vcam-1 (Figure 5). In general, most of the
above factors are up-regulated in the presence of IFN, and exacerbate inflammation. Conversely, 11 out
of the modified 17 factors are down-regulated. These factors, namely angiopoietin-2, BDNF, FGF basic,
FGF-19, IL1α, IL5, kallikrein 3, MIF, MMP-9, TARC/CCL17, and TFR/CD71 (Figure 5), are growth
factors involved mainly in cell migration.
We also showed that exposures to TII as short as 2 h were associated with significant changes in
the entire mTOR pathway (Figure 8); this finding is in keeping with previous observations by ourselves
and other groups in other microglia models [21–23].
As far as microglial activation towards an M2 phenotype is concerned, the cytokines IL4 or IL13
alone or in association with IL10 are typically used as stimuli. In our experimental paradigm, we first
chose to try cytokines alone, but we did not obtain reproducible data, so we decided not to go ahead
with the stimulation in association. In fact, we failed to activate IMHU towards a complete type
M2 phenotype: while we were able to induce increases in urea release, such increase was not fully
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reproducible. Moreover, stimulation with IL4 elicited an increase production of factors that are not
taken as markers of M2 profiling. In addition, the data obtained after activation with IL4 or IL13
depend on the medium used, and, therefore, this type of activation deserves a detailed study to find
the right conditions. However, in our opinion too strict and complicated protocol lead the use of a
cellular line too far from the possibility of having translational data.
5. Conclusions
In conclusion, IMhu cells proved to be a useful experimental model to investigate the
physiopathology of microglia cells, including pathological conditions that involve the mTOR pathway.
IMhu cells partially addressed a need for human models of microglia; however, considering that
in vitro studies in the field usually require demonstrations based on more than one cellular model,
the quest for additional tools remains still unsatisfied.
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